HEMABATE Drug Patent Profile

When do Hemabate patents expire, and when can generic versions of Hemabate launch?

Hemabate is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in HEMABATE is carboprost tromethamine. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the carboprost tromethamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hemabate

A generic version of HEMABATE was approved as carboprost tromethamine by DR REDDYS on July 2^nd, 2019.

Summary for HEMABATE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for HEMABATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	HEMABATE	carboprost tromethamine	INJECTABLE;INJECTION	017989-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes

International Patents for HEMABATE

See the table below for patents covering HEMABATE around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	57582
France	2100627
Malaysia	7400305	IMPROVEMENTS IN OR RELATING TO PROSTAGLANDINS AND THE PREPARATION THEREOF
Switzerland	578496

HEMABATE Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is Hemabate, and Why Is It Relevant for Investment?

Hemabate (carboprost tromethamine) is a prostaglandin analogue approved primarily for controlling postpartum hemorrhage and inducing abortions. Its commercial relevance stems from its clinical use in obstetrics and gynecology, particularly in regions with high maternal mortality rates. The drug's market potential is influenced by regulatory approvals, patent status, safety profiles, and demand driven by maternal health initiatives.

What Are the Regulatory and Patent Statuses of Hemabate?

Hemabate is marketed by Pfizer (formerly by Pharmacia & Upjohn), with U.S. patent protection expiring in 2017. Key regulatory milestones include:

• FDA Approval: 2000 for postpartum hemorrhage.
• Global Marketing: Approved in numerous countries, including in Europe (by the EMA) and emerging markets.

Patent expirations have allowed generic manufacturers to enter the market, increasing competition and potentially reducing pricing power.

What Is Hemabate’s Market Size and Growth Dynamics?

Global Market (2022 Data):

Region	Estimated Market Size	Compound Annual Growth Rate (CAGR, 2022-2027)
North America	$50 million	2%
Europe	$45 million	1.8%
Asia-Pacific	$30 million	3.5%
Rest of World	$10 million	2.5%

Total estimated global market: approximately $135 million in 2022.

Key Drivers:

• Growing global maternal health awareness.
• Increasing cesarean section rates.
• Expanding healthcare infrastructure in emerging markets.

Limitations:

• Price sensitivity in low-income regions.
• Competition from alternative therapies.

What Are the Competitive and Commercial Challenges?

• Generic Competition: Post-2017, multiple generics entered, eroding market share for originator products.
• Safety Profile: Risks of bronchospasm and hypotension limit use to carefully monitored settings.
• Regulatory Variability: Differing approval statuses influence market access.

What Are the R&D and Pipeline Opportunities?

Despite current use limitations, potential pipelines include:

• New Formulations: Development of more stable or targeted delivery methods.
• Alternative Indications:Research into off-label uses such as labor induction or treatment of specific obstetric conditions.

However, the drug's niche status and safety concerns constrain substantial innovation-driven growth.

What Is the Investment Outlook Based on Fundamentals?

• Market Maturity: The drug's market is mature with slow growth and significant generic competition.
• Pricing Trends: As patents expire, pricing pressure increases.
• Regulatory Risks: Variability in approvals may impact global access.
• Patent Landscape: The patent expiry limits exclusivity; future R&D investments may face hurdles.

Investors should consider Hemabate’s role within broader obstetric drug portfolios rather than as a standalone high-growth asset.

Key Takeaways

Hemabate operates in a niche market with limited growth prospects due to patent expirations and competition. While maintaining steady demand in obstetrics, future revenues depend on regional health policies, safety management, and generic competition. Investment strategies should weigh these factors against the overall size and stability of its market.

FAQs

1. What is the primary clinical use of Hemabate?

Control of postpartum hemorrhage and induction of abortion procedures in obstetrics.

2. How does patent expiry affect Hemabate’s market?

It allows generic manufacturers to produce cheaper versions, reducing revenue potential for originators and intensifying price competition.

3. Are there new indications or formulations under development?

Current research focuses on formulation improvements but little evidence suggests significant expansion into new indications.

4. What regulatory challenges could impact Hemabate’s future sales?

Differing approvals and safety concerns in various regions may restrict or delay market access.

5. How does Hemabate compare with alternative therapies?

It is often used where other medications are ineffective or contraindicated, but safety profiles and cost are influencing factors for clinical choice.

---

Sources:

[1] Pfizer annual reports and product dossiers.
[2] Global Market Insights. "Obstetric Drugs Market Forecast," 2022-2027.
[3] U.S. FDA approved drug labels.
[4] European Medicines Agency database.